{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:21:56Z","timestamp":1760235716162,"version":"build-2065373602"},"reference-count":25,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T00:00:00Z","timestamp":1631923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and objectives: this study assessed variations in the blood parameters of patients with hematological disorders infected with HCV throughout a 12-week interferon-free treatment regimen. Materials and methods: We followed a total of 344 patients suffering from chronic hepatitis C, infected with the 1b genotype and concomitant hematological disorders, who benefited from the direct-acting antiviral (DAA) therapy in our clinic. Seven of the most routinely checked blood parameters were analyzed, namely, hemoglobin, leucocyte count, neutrophils, erythrocyte count, platelet count, ALT, and total bilirubin level. In total, 129 patients received a treatment scheme comprising ombitasvir, paritaprevir, ritonavir, and dasabuvir, while the 215 other patients received a sofosbuvir and ledipasvir regimen. Results: Patients enrolled in the study showed remarkably increased ALT levels in the first four weeks of DAA treatment, normalizing to levels below 40 U\/L by the end of regimen. There were no other blood parameters that worsened throughout the 12-week regimen to levels below our laboratory\u2019s normal range. After 12 weeks of DAA therapy, 309 patients (90%) achieved SVR. Conclusions: Our findings are consistent in evaluating the efficacy and tolerability of direct-acting antivirals for 1b genotype HCV infected patients with associated hematological malignancies under remission, and other hematological disturbances, that were previously unsuccessfully treated with a pegylated interferon regimen. Thus, paving a pathway for government-funded programs being implemented in this direction.<\/jats:p>","DOI":"10.3390\/medicina57090986","type":"journal-article","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T22:34:01Z","timestamp":1632263641000},"page":"986","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Direct-Acting Antiviral Use for Genotype 1b Hepatitis C Patients with Associated Hematological Disorders from Romania"],"prefix":"10.3390","volume":"57","author":[{"given":"Iosif","family":"Marincu","sequence":"first","affiliation":[{"name":"Methodological and Infectious Diseases Research Center, Department of Infectious Diseases, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4711-4315","authenticated-orcid":false,"given":"Felix","family":"Bratosin","sequence":"additional","affiliation":[{"name":"Methodological and Infectious Diseases Research Center, Department of Infectious Diseases, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Curescu","sequence":"additional","affiliation":[{"name":"Methodological and Infectious Diseases Research Center, Department of Infectious Diseases, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oana","family":"Suciu","sequence":"additional","affiliation":[{"name":"Methodological and Infectious Diseases Research Center, Department of Infectious Diseases, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirela","family":"Turaiche","sequence":"additional","affiliation":[{"name":"Methodological and Infectious Diseases Research Center, Department of Infectious Diseases, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Cerbu","sequence":"additional","affiliation":[{"name":"Methodological and Infectious Diseases Research Center, Department of Infectious Diseases, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9234-5767","authenticated-orcid":false,"given":"Iulia","family":"Vidican","sequence":"additional","affiliation":[{"name":"Methodological and Infectious Diseases Research Center, Department of Infectious Diseases, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Bartenschlager, R., and B\u00fchler, S. (2008). Hepatitis C Virus. Encyclopedia of Virology, Academic Press.","DOI":"10.1016\/B978-012374410-4.00416-7"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Falla, A.M., Ahmad, A.A., Duffell, E., Noori, T., and Veldhuijzen, I.K. (2018). Estimating the scale of chronic hepatitis C virus infection in the EU\/EEA: A focus on migrants from anti-HCV endemic countries. BMC Infect. Dis., 18.","DOI":"10.1186\/s12879-017-2908-5"},{"key":"ref_3","unstructured":"The Polaris Observatory HCV Collaborators (2017). Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modeling study. Lancet Gastroenterol. Hepatol., 2, 161\u2013176."},{"key":"ref_4","unstructured":"Constantin, M., Cernea, A., Dejoianu, T.C., and Lupu, I. (2020). Prevalence of Viral Hepatitis B and Viral Hepatitis C Infection among Health Care Providers from Adult and Children Health Care and Social Assistance Centers, Centrul Medical de Diagnostic si Tratament \u201cDr. Victor Babes\u201d. Available online: https:\/\/www.cdt-babes.ro\/cercetare\/prevalence-of-hbv-and-hcv-infection-among-health-care-providers.pdf."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.gtc.2015.07.003","article-title":"Natural History of Hepatitis C","volume":"44","author":"Lingala","year":"2015","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"ref_6","first-page":"S35","article-title":"The natural history of chronic hepatitis C","volume":"36","author":"Seef","year":"2002","journal-title":"Hepatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/ilar.42.2.107","article-title":"Hepatitis C: A brief clinical overview","volume":"42","author":"Strader","year":"2001","journal-title":"ILAR J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/qjmed\/hcs239","article-title":"Liver disease as a cause of thrombocytopenia","volume":"106","author":"Hancox","year":"2013","journal-title":"QJM"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1086\/423384","article-title":"Strong association of hepatitis C virus (HCV) infection and thrombocytopenia: Implications from a community survey with hyperendemic HCV infection","volume":"39","author":"Wang","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Krishnan, S.M., and Dixit, N.M. (2011). Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy. PLoS Comput. Biol., 7.","DOI":"10.1371\/journal.pcbi.1001072"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/00004836-200109000-00014","article-title":"Chronic hepatitis C virus infection associated with primary warm-type autoimmune hemolytic anemia","volume":"33","author":"Chao","year":"2001","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_12","first-page":"256","article-title":"Autoimmune hemolytic anemia in chronic hepatitis C virus infection: An unusual extrahepatic autoimmune manifestation","volume":"16","author":"Moccia","year":"2001","journal-title":"Ann. Ital. Med. Int."},{"key":"ref_13","first-page":"140953","article-title":"Evolution of Interferon-Based Therapy for Chronic Hepatitis C","volume":"2010","year":"2010","journal-title":"Hepat. Res. Treat."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"11631","DOI":"10.18632\/oncotarget.24391","article-title":"Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: Higher SVR rates with special precautions for deterioration of autoimmune hepatitis","volume":"9","author":"Kanda","year":"2018","journal-title":"Oncotarget"},{"key":"ref_15","unstructured":"Centers for Disease Control and Prevention (2013). Testing for HCV infection: An update of guidance for clinicians and laboratorians. MMWR Morb. Mortal. Wkly. Rep., 62, 362\u2013365."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.4254\/wjh.v7.i12.1617","article-title":"Predictive factors associated with hepatitis C antiviral therapy response","volume":"7","author":"Cavalcante","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_17","first-page":"433","article-title":"Comparison of hepatitis C viral loads in patients with or without co-infection with different genotypes","volume":"11","author":"Schijman","year":"2004","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s00261-015-0373-4","article-title":"Ultrasound elastography: Liver","volume":"40","author":"Dhyani","year":"2015","journal-title":"Abdom. Imaging"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Iliescu, E.L., Mercan-Stanciu, A., and Toma, L. (2020). Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease. BMC Nephrol., 21.","DOI":"10.1186\/s12882-020-1687-1"},{"key":"ref_20","unstructured":"American Association for the Study of Liver Diseases and Infectious Diseases Society of America (2020, October 01). HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Available online: www.hcvguidelines.org\/full-report-view."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"215","DOI":"10.5114\/ceh.2019.87634","article-title":"Effect of comedication on ombitasvir\/paritaprevir\/ritonavir \u00b1 dasabuvir \u00b1 ribavirin therapy in chronic hepatitis C\u2014a real-world study","volume":"5","author":"Simon","year":"2019","journal-title":"Clin. Exp. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4103\/mmj.mmj_55_19","article-title":"Effect of direct-acting antiviral agents on hepatitis C virus-associated thrombocytopenia","volume":"33","author":"Shoeib","year":"2020","journal-title":"Menoufia Med. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/apt.13825","article-title":"Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer","volume":"44","author":"Economides","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1080\/14656566.2016.1176143","article-title":"Ombitasvir\/paritaprevir\/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection","volume":"17","author":"Flisiak","year":"2016","journal-title":"Expert Opin. Pharmacother."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/9\/986\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:01:57Z","timestamp":1760166117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/9\/986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,18]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["medicina57090986"],"URL":"https:\/\/doi.org\/10.3390\/medicina57090986","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2021,9,18]]}}}